192 related articles for article (PubMed ID: 6223812)
1. In vitro activity of teichomycin A 2 in comparison with penicillin and vancomycin against gram-positive cocci.
Bauernfeind A; Petermüller C
Eur J Clin Microbiol; 1982 Oct; 1(5):278-81. PubMed ID: 6223812
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci.
Tuazon CU; Miller H
Antimicrob Agents Chemother; 1984 Apr; 25(4):411-2. PubMed ID: 6233934
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of teichomycin against isolates of gram-positive bacteria.
Fietta A; Bersani C; Mangiarotti P; Gialdroni Grassi G
Chemotherapy; 1983; 29(4):275-82. PubMed ID: 6223793
[TBL] [Abstract][Full Text] [Related]
4. In-vitro comparison of the post-antibiotic effect of vancomycin and teicoplanin.
Cooper MA; Jin YF; Ashby JP; Andrews JM; Wise R
J Antimicrob Chemother; 1990 Aug; 26(2):203-7. PubMed ID: 2145256
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of teicoplanin against gram-positive cocci.
Allouch P; Pina P; Chaplain C; Delarbre JM; Geffroy F; Grasmick CP; Marcolin M; Morel A; Pangon B; Rio Y; Sédaillan A
Pathol Biol (Paris); 2000 Oct; 48(8):792-5. PubMed ID: 11244609
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus.
Guenthner SH; Wenzel RP
Antimicrob Agents Chemother; 1984 Aug; 26(2):268-9. PubMed ID: 6237606
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of the new glycopeptide decaplanin.
Neu HC; Chin NX; Niu WW
Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):458-62. PubMed ID: 1330562
[TBL] [Abstract][Full Text] [Related]
8. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
Bezian MC; Ribou G; Masquelier B
Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of gram-positive cocci to paldimycin.
Pohlod DJ; Saravolatz LD; Somerville MM
Antimicrob Agents Chemother; 1987 Jan; 31(1):104-7. PubMed ID: 3105438
[TBL] [Abstract][Full Text] [Related]
10. [The invitro activity of teicoplanin and vancomycin against gram positive microorganisms (corrected)].
Kayaokay Y; Hasçelik G; Gür D; Akalin E
Mikrobiyol Bul; 1991 Oct; 25(4):321-5. PubMed ID: 1839050
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
Machka K; Braveny I
Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
[TBL] [Abstract][Full Text] [Related]
12. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of teichomycin compared with those of other antibiotics.
Neu HC; Labthavikul P
Antimicrob Agents Chemother; 1983 Sep; 24(3):425-8. PubMed ID: 6227282
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
Shonekan D; Mildvan D; Handwerger S
Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships in the series of eremomycin carboxamides.
Miroshnikova OV; Printsevskaya SS; Olsufyeva EN; Pavlov AY; Nilius A; Hensey-Rudloff D; Preobrazhenskaya MN
J Antibiot (Tokyo); 2000 Mar; 53(3):286-93. PubMed ID: 10819300
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci.
Cynamon MH; Granato PA
Antimicrob Agents Chemother; 1982 Mar; 21(3):504-5. PubMed ID: 6213192
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of everninomicin against clinical isolates of Enterococcus spp., Staphylococcus spp., and Streptococcus spp. tested by Etest.
Terakubo S; Takemura H; Yamamoto H; Ikejima H; Kunishima H; Kanemitsu K; Kaku M; Shimada J
J Infect Chemother; 2001 Dec; 7(4):263-6. PubMed ID: 11810596
[TBL] [Abstract][Full Text] [Related]
18. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
20. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
Pohlod DJ; Saravolatz LD; Somerville MM
J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
